Dixon Technologies reported a 36% YoY drop in Q4 consolidated PAT to Rs 256 crore despite a 2% rise in revenue to Rs 10,511 crore. EBITDA improved 9%, while the board recommended a Rs 10 per share dividend. The stock fell over 6% after the earnings announcement.
Dr Reddy’s Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announced
Dr Reddy’s Laboratories Q4 Results: Dr. Reddy’s Laboratories reported a consolidated net profit at Rs 221 crore in the March-ended quarter versus Rs 1,587 crore